SCHEMBL4287899

SCHEMBL4287899

Cn1cc(-c2ccc(N3CCC4(CC3)CCN(C3CCC3)CC4)cc2)cnc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.43
TLR4 O00206 1/20 0.42
TLR9 Q9NR96 1/20 0.42
TLR8 Q9NR97 1/20 0.42
TLR7 Q9NYK1 1/20 0.42
USP2 O75604 5/20 0.38
CYP1A2 P05177 4/20 0.38
CYP2C19 P33261 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP2C9 P11712 2/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPK1 P28482 2/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
CYP3A4 P08684 4/20 0.38
TSHR P16473 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 2/20 0.38
L3MBTL3 Q96JM7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4935016 0.84 TLR4 (0.49) HRH3TLR4TLR9TLR8TLR7
SCHEMBL4280699 0.83 CHRM1 (0.44) HRH3USP2CYP1A2CYP2C19ALDH1A1
SCHEMBL4141357 0.78 HRH3 (0.45) HRH3TLR4TLR9TLR8TLR7
SCHEMBL4131621 0.77 DYRK1A (0.45) HRH3TLR9TLR7USP2CYP1A2
SCHEMBL4282555 0.77 CHRM1 (0.48) HRH3CYP3A4CHRM1
SCHEMBL4286110 0.77 HRH3 (0.47) HRH3TLR4TLR9TLR8TLR7
SCHEMBL4136957 0.77 HRH3 (0.47) HRH3USP2CYP1A2CYP2C19ALDH1A1
SCHEMBL4287909 0.76 CHRM1 (0.45) HRH3USP2CYP1A2CYP2C19ALDH1A1
SCHEMBL4931504 0.76 CYP3A4 (0.50) HRH3USP2CYP1A2CYP2C19CYP2C9
SCHEMBL4288657 0.75 HRH3 (0.45) HRH3TLR4TLR9TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 HRH3 1/4885TLR4 1483/4885TLR9 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.